Pérez-Corona G, Aguilar-Salinas P, Álvarez-Bojorges AL, Aranda-Martínez A, Gutiérrez-Ruiz GN, Ventura Claudia V, Ávalos-Reyes D, Paz FJ, Badillo-Santoyo MA, Maldonado-Valadez R, Negrete-Pulido Ó, Manzo G, Urbieta-Landeros MJ

Language: Spanish
References: 10
Page: 157-161
PDF size: 400.23 Kb.

ABSTRACT

Aims: To identify the prevalence of prostate cancer (CaP) in the population attended to at the Hospital Regional de Alta Especialidad del Bajío (HRAEB) over the last four years and the association with prostate specific antigen (PSA) values and digital rectal examination (DRE) of the prostate.
Materials and methods: A retrospective, observational, descriptive, cross-sectional study was carried out in which 239 medical records of patients that had at least one histopathologic study of the prostate obtained through transrectal ultrasound-guided prostate biopsy (TRUPB), transurethral resection of the prostate (TURP), or radical prostatectomy (RP) from the period that was analyzed. Each medical record was evaluated in relation to patient age, DRE, and PSA value before biopsy and histopathologic diagnosis.
Results: Nine patients were excluded, the mean age was 68.62 years, 35 suspicious DREs were registered, and the mean PSA was 32.75 ng/dL. Seventy-six (31.8%) cases of adenocarcinoma were detected, 5 (2.09%) cases of benign prostatic hyperplasia (BPH), 2 (0.84%) cases of chronic prostatitis, 145 (60.67%) cases of BPH/chronic prostatitis, and 2 (0.84%) cases of prostatic intraepithelial neoplasia (PIN). In the patients with CaP, the PSA range was 4 – 792 ng/dL, 40.78% of the cases had a Gleason score of 6, and the mean age was 69.5 years.
Conclusions: Our diagnostic capacity is delayed because patients are referred to us from primary and secondary care centers. A network for the “detection and treatment of CaP” in the State of Guanajuato is being constructed for the referral of at-risk patients to the HRAEB.

REFERENCES

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61(2):69-90.

2. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61(4):212-236.

3. Consultado el 15 de julio de 2012. [http://sinais.salud.gob.mx/mortalidad/]

4. Consultado el 15 de julio de 2012. http://www.salud.gob.mx/unidades/cdi/documentos/cancer_prostata.pdf

5. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤ 4.0 ng per milliliter. N Engl J Med 2004;350(22):2239-2246.

6. Jain S, Bhojwani AG, Mellon JK. Improving the utility of prostate specific antigen (APE) in the diagnosis of prostate cancer: the use of APE derivatives and novel markers. Postgrad Med J 2002;78(925):646-650.

7. Wolf A, Wender R, Etzioni RB, et al. American Cancer Society Guideline for the Early Detection of Prostate Cancer (update 2010). CA Cancer J Clin 2010;60(2):70-98.

8. Hodge K, McNeal JE, Terris MK, et al. Random systematic versus directed Ultrasound guided transrectal core biopsies of the Prostate. J Urol 1989;142(1):71-74.

9. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008;149(3):185-191.

10. Gómez-Guerra LS, Martínez-Fierro ML, Alcantara-Aragon V, et al. Population based prostate cancer screening in north Mexico reveals a high prevalence of aggresive tumors in detected cases. BMC Cancer 2009;9:91.